Mexico began talks with Italy with the aim of producing in the national territory the Italian vaccine GRAd-COV2, which has an efficacy of up to 99 percent in neutralizing the pathogen.
In a statement, the Ministry of Foreign Affairs explained that the Undersecretary for Multilateral Affairs and Human Rights, Martha Delgado, met this Wednesday in Castel Romano, Italy, with Francesco Vaia, director of the Lazzaro Spallanzani National Institute of Infectious Diseases, as well as with officials from the Lazio region and executives of the pharmaceutical company ReiThera, with the aim of advancing in a possible cooperation project.
During the meeting, it was highlighted that the GRAd-COV2 vaccine is ready to continue with phase 3 of the development process, once phase 2 of tests has concluded, which, according to ReiThera, showed that it has an efficacy of 93 percent three weeks after the first dose and 99 percent after the second.
Likewise, it is expected that the vaccine will soon have the permission for emergency use of the European Medicines Agency, which would allow it to be compared with other already established vaccine platforms, which are currently used against COVID-19.
Regarding the possibility of producing the GRAd-COV2 vaccine in Mexico, it was pointed out that said production could occur through various schemes, such as joint ventures, technology transfer and / or sales. Also, the possibility was opened that phase 3 clinical studies of the vaccine could be carried out in Mexico, for which it would be necessary to have six thousand volunteers in our country.